Literature DB >> 32647636

Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma.

Ryota Matsuki1, Kirio Kawai2, Yutaka Suzuki1, Masaharu Kogure1, Tetsuya Nakazato1, Daisuke Naruge2, Naohiro Okano2, Satowa Seki3, Yoshihiko Ohmori4, Naohiro Kawamura3, Hiroshi Kamma4, Tadakazu Hisamatsu3, Junji Shibahara4, Toshiyuki Mori1, Junji Furuse2, Yoshihiro Sakamoto1.   

Abstract

Entities:  

Year:  2020        PMID： 32647636      PMCID： PMC7325124          DOI： 10.1159/000506202

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  5 in total

1.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

2.  Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Authors:  Riccardo Lencioni; Robert Montal; Ferran Torres; Joong-Won Park; Thomas Decaens; Jean-Luc Raoul; Masatoshi Kudo; Charissa Chang; José Ríos; Valerie Boige; Eric Assenat; Yoon-Koo Kang; Ho-Yeong Lim; Ian Walters; Josep M Llovet
Journal:  J Hepatol       Date:  2017-01-26       Impact factor: 25.083

Review 3.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

4.  Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.

Authors:  Sabine Irtan; Xavier Chopin-Laly; Maxime Ronot; Sandrine Faivre; Valérie Paradis; Jacques Belghiti
Journal:  Liver Int       Date:  2011-01-11       Impact factor: 5.828

5.  Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.

Authors:  Junichi Shindoh; Evelyne M Loyer; Scott Kopetz; Piyaporn Boonsirikamchai; Dipen M Maru; Yun Shin Chun; Giuseppe Zimmitti; Steven A Curley; Chusilp Charnsangavej; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544
  5 in total
  4 in total

1.  Regression of Tumor Thrombus in the Suprahepatic Vena Cava of Hepatocellular Carcinoma and Conversion Hepatectomy Induced by Lenvatinib.

Authors:  Ryota Matsuki; Naohiro Okano; Takaaki Arai; Shinya Yoshiike; Masaharu Kogure; Yutaka Suzuki; Junji Shibahara; Junji Furuse; Yoshihiro Sakamoto
Journal:  Liver Cancer       Date:  2021-11-11       Impact factor: 12.430

Review 2.  New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2022-05-08       Impact factor: 3.850

3.  Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.

Authors:  Yuki Ohya; Shintaro Hayashida; Akira Tsuji; Kunitaka Kuramoto; Hidekatsu Shibata; Hiroko Setoyama; Hironori Hayashi; Kazumi Kuriwaki; Masato Sasaki; Masayoshi Iizaka; Osamu Nakahara; Yukihiro Inomata
Journal:  Surg Case Rep       Date:  2020-12-10

4.  Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report.

Authors:  Yutaka Endo; Motohide Shimazu; Tadayuki Sakuragawa; Yusuke Uchi; Motonori Edanami; Ken Sunamura; Soji Ozawa; Naokazu Chiba; Shigeyuki Kawachi
Journal:  World J Gastrointest Surg       Date:  2022-03-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.